Elsevier Inc.

SHERPA: Unknown

People

  1. Mulhall
    Mulhall
  2. Zelefsky
    Zelefsky
  3. Giralt
    Giralt
  4. Lee
    Lee
  5. Chi
    Chi
  6. Wolden
    Wolden
  7. Yorke
    Yorke
  8. Perales
    Perales
  9. Abu-Rustum
    Abu-Rustum
  10. Fuks
    Fuks

Groups

  1. Surgery (2685)
  2. Survivorship Research (2022)
  3. Solid Tumor Oncology Division (1908)
  4. Radiation Oncology, Department of (1861)
  5. GSK Faculty (1567)
  6. Center for Hematologic Malignancies (1294)
  7. Sloan Kettering Institute Faculty (1273)
  8. Medical Physics (916)
  9. Epidemiology and Biostatistics (819)
  10. Hematologic Malignancies, Division of (789)
Search Within
Refine Results
Formats
  1. Journal Article (6265)
  2. Meeting Abstract (3290)
  3. Book Section (215)
  4. Review (127)
  5. Conference Paper (116)
  6. Editorial (48)
  7. Guidelines (21)
  8. Correspondence (20)
  9. Research Letter (7)
  10. Book Whole (5)
  11. Miscellaneous (4)
Groups
  1. Surgery (2685)
  2. Survivorship Research (2022)
  3. Solid Tumor Oncology Division (1908)
  4. Radiation Oncology, Department of (1861)
  5. GSK Faculty (1567)
  6. Center for Hematologic Malignancies (1294)

More Groups

People
  1. Richard Barakat (371)
  2. Michael Zelefsky (367)
  3. Dennis Chi (354)
  4. Nadeem Abu-Rustum (340)
  5. Nancy Lee (332)
  6. Sergio Giralt (307)

More People

Years
  1. 2021 (256)
  2. 2020 (673)
  3. 2019 (627)
  4. 2018 (661)
  5. 2017 (592)
  6. 2016 (506)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2029)
  2. Gynecologic Oncology (914)
  3. Biology of Blood and Marrow Transplantation (816)
  4. Journal of Thoracic Oncology (702)
  5. European Journal of Cancer (427)
  6. Journal of Sexual Medicine (331)

More Publications

Results (10118)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours
    Meeting Abstract

    Gettinger, S.; Kluger, H.; Schoenfeld, A.; Betof Warner, A.; He, K.; Sukari, A.; Thomas, S. S.; de SpeĢville, B. D.; Lee, S.; Haefliger, S.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation
    Meeting Abstract

    Riely, G. J.; Ou, S. H. I.; Rybkin, I.; Spira, A.; Papadopoulos, K.; Sabari, J. K.; Johnson, M.; Heist, R. S.; Bazhenova, L.; Barve, M.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
    Meeting Abstract

    Moreno Garcia, V.; Lin, J.; Patel, J.; Lassen, U.; Solomon, B.; Rosen, L.; Leyvraz, S.; Tan, D. S. W.; Reeves, J. A.; Beckmann, G.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with METexon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A
    Meeting Abstract

    Scherz, A.; Sakai, H.; Le, X.; Felip, E.; Veillon, R.; Garassino, M. C.; Raskin, J.; Viteri, S.; Mazieres, J.; Cortot, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
    Meeting Abstract

    Paz-Ares, L.; Owonikoko, T. K.; Johnson, M.; Govindan, R.; Izumi, H.; Lai, V.; Borghaei, H.; Boyer, M.; Boosman, R. J.; Hummel, H. D.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy
    Meeting Abstract

    Spigel, D. R.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; May, R.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2 trial of MRTX849 in combination with pembrolizumab in patients with advanced non-small cell lung cancer with KRAS G12C mutation
    Meeting Abstract

    Spira, A.; Riely, G.; Lawler, W.; Shum, M.; Socinski, M.; Yanagihara, R.; Roshan, S.; Kheoh, T.; Christensen, J.; Chao, R.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
    Meeting Abstract

    Schram, A.; Macarulla, T.; O'Reilly, E.; Rodon, J.; Wolpin, B.; Ou, S.; Kim, D.; Yang, J. C.; Lam, J.; De Langen, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2 study of erdafitinib in patients with advanced solid tumors and fibroblast growth factor receptor gene alterations
    Meeting Abstract

    Pant, S.; Tabernero, J.; Massard, C.; Hyman, D. M.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Activity of tepotinib in brain metastases (BM): Preclinical and clinical data in MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Mazieres, J.; Veillon, R.; Felip, E.; Le, X.; Garassino, M. C.; Stanton, T.; Morise, M.; Lee, J.; Matsumoto, S.; De Marinis, F.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save